repro med sys - KRMD
KRMD
Close Chg Chg %
5.57 0.10 1.80%
Closed Market
5.67
+0.10 (1.80%)
Volume: 159.26K
Last Updated:
Jan 15, 2026, 4:00 PM EDT
Company Overview: repro med sys - KRMD
KRMD Key Data
| Open $5.58 | Day Range 5.56 - 5.86 |
| 52 Week Range 1.87 - 6.61 | Market Cap $258.02M |
| Shares Outstanding 46.32M | Public Float 43.76M |
| Beta 0.51 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 173.12K |
KRMD Performance
| 1 Week | 0.35% | ||
| 1 Month | -2.24% | ||
| 3 Months | 40.00% | ||
| 1 Year | 38.63% | ||
| 5 Years | 8.41% |
KRMD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About repro med sys - KRMD
KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.
KRMD At a Glance
KORU Medical Systems, Inc.
100 Corporate Drive
Mahwah, New Jersey 07430
| Phone | 1-845-469-2042 | Revenue | 33.65M | |
| Industry | Medical Specialties | Net Income | -6,066,633.00 | |
| Sector | Health Technology | 2024 Sales Growth | 17.985% | |
| Fiscal Year-end | 12 / 2025 | Employees | 80 | |
| View SEC Filings |
KRMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.241 |
| Price to Book Ratio | 10.523 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -30.723 |
| Enterprise Value to Sales | 5.075 |
| Total Debt to Enterprise Value | 0.023 |
KRMD Efficiency
| Revenue/Employee | 420,580.787 |
| Income Per Employee | -75,832.913 |
| Receivables Turnover | 5.61 |
| Total Asset Turnover | 1.182 |
KRMD Liquidity
| Current Ratio | 2.657 |
| Quick Ratio | 2.267 |
| Cash Ratio | 1.33 |
KRMD Profitability
| Gross Margin | 60.759 |
| Operating Margin | -19.159 |
| Pretax Margin | -18.022 |
| Net Margin | -18.031 |
| Return on Assets | -21.318 |
| Return on Equity | -32.645 |
| Return on Total Capital | -29.161 |
| Return on Invested Capital | -27.561 |
KRMD Capital Structure
| Total Debt to Total Equity | 23.731 |
| Total Debt to Total Capital | 19.179 |
| Total Debt to Total Assets | 14.022 |
| Long-Term Debt to Equity | 19.05 |
| Long-Term Debt to Total Capital | 15.396 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Repro Med Sys - KRMD
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 23.49M | 27.90M | 28.52M | 33.65M | |
Sales Growth
| -2.84% | +18.76% | +2.23% | +17.98% | |
Cost of Goods Sold (COGS) incl D&A
| 10.18M | 13.11M | 12.68M | 13.20M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 463.13K | 587.14K | 870.39K | 888.47K | |
Depreciation
| 399.30K | 524.99K | 805.92K | 820.28K | |
Amortization of Intangibles
| 63.83K | 62.14K | 64.47K | 68.20K | |
COGS Growth
| +5.43% | +28.78% | -3.31% | +4.13% | |
Gross Income
| 13.31M | 14.78M | 15.84M | 20.44M | |
Gross Income Growth
| -8.34% | +11.09% | +7.14% | +29.08% | |
Gross Profit Margin
| +56.65% | +52.99% | +55.54% | +60.76% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 20.34M | 25.56M | 26.11M | 26.89M | |
Research & Development
| 2.47M | 4.96M | 5.74M | 5.26M | |
Other SG&A
| 17.86M | 20.61M | 20.37M | 21.63M | |
SGA Growth
| +53.72% | +25.70% | +2.13% | +2.99% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (7.03M) | (10.78M) | (10.27M) | (6.45M) | |
Non Operating Income/Expense
| 665.09K | 105.72K | 496.40K | 382.49K | |
Non-Operating Interest Income
| 13.08K | 145.59K | 561.33K | 444.64K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (6.36M) | (10.68M) | (9.77M) | (6.06M) | |
Pretax Income Growth
| -432.92% | -67.73% | +8.45% | +37.96% | |
Pretax Margin
| -27.09% | -38.27% | -34.27% | -18.02% | |
Income Tax
| (1.80M) | (2.01M) | 3.97M | 2.89K | |
Income Tax - Current - Domestic
| - | 12.80K | 6.00M | 2.89K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | (1.81M) | (2.01M) | (2.04M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (4.56M) | (8.66M) | (13.74M) | (6.07M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (4.56M) | (8.66M) | (13.74M) | (6.07M) | |
Net Income Growth
| -276.45% | -89.82% | -58.65% | +55.85% | |
Net Margin Growth
| -19.42% | -31.05% | -48.18% | -18.03% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (4.56M) | (8.66M) | (13.74M) | (6.07M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (4.56M) | (8.66M) | (13.74M) | (6.07M) | |
EPS (Basic)
| -0.1028 | -0.1925 | -0.3013 | -0.1325 | |
EPS (Basic) Growth
| -255.71% | -87.26% | -56.52% | +56.02% | |
Basic Shares Outstanding
| 44.39M | 45.00M | 45.60M | 45.80M | |
EPS (Diluted)
| -0.1028 | -0.1925 | -0.3013 | -0.1325 | |
EPS (Diluted) Growth
| -255.71% | -87.26% | -56.52% | +56.02% | |
Diluted Shares Outstanding
| 44.39M | 45.00M | 45.60M | 45.80M | |
EBITDA
| (6.57M) | (10.19M) | (9.40M) | (5.56M) | |
EBITDA Growth
| -484.74% | -55.24% | +7.79% | +40.87% | |
EBITDA Margin
| -27.95% | -36.54% | -32.96% | -16.52% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 6.25 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.015 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.017 | |
| Last Quarter’s Earnings | -0.02 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.066 | Next Fiscal Year Estimate | 0.04 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 5 | 3 |
| Mean Estimate | -0.02 | -0.01 | -0.02 | 0.04 |
| High Estimates | -0.01 | 0.00 | 0.01 | 0.05 |
| Low Estimate | -0.02 | -0.01 | -0.03 | 0.02 |
| Coefficient of Variance | -33.04 | -80.86 | -95.39 | 43.30 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Repro Med Sys - KRMD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Repro Med Sys - KRMD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 24, 2025 | Linda M. Tharby Chief Executive Officer; Director | 1,085,411 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Linda M. Tharby Chief Executive Officer; Director | 1,076,563 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.89 per share | 3,111,267.07 |
| Mar 24, 2025 | Linda M. Tharby Chief Executive Officer; Director | 1,046,750 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.83 per share | 2,962,302.50 |
| Mar 24, 2025 | Linda M. Tharby Chief Executive Officer; Director | 47,904 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Christopher Pazdan Chief Operating Officer | 49,784 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Christopher Pazdan Chief Operating Officer | 48,143 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.89 per share | 139,133.27 |
| Mar 24, 2025 | Christopher Pazdan Chief Operating Officer | 84,474 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Christopher Pazdan Chief Operating Officer | 71,625 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.83 per share | 202,698.75 |
| Mar 24, 2025 | Christopher Pazdan Chief Operating Officer | 15,192 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Christopher Pazdan Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Thomas Adams Chief Financial Officer | 5,404 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Thomas Adams Chief Financial Officer | 3,416 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.89 per share | 9,872.24 |
| Mar 24, 2025 | Thomas Adams Chief Financial Officer | 16,212 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Kenneth Miller Chief Commercial Officer | 5,893 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Kenneth Miller Chief Commercial Officer | 3,725 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.89 per share | 10,765.25 |
| Mar 24, 2025 | Kenneth Miller Chief Commercial Officer | 17,679 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |